Search Results

Two weeks after a massive transfusion protocol for hemorrhagic shock, one of our patients developed profound thrombocytopenia — counts dropping to single digits despite transfusions. Each additional platelet unit seemed to make things worse, not better. Within days, she developed intra-abdominal bleeding that required surgical exploration and an open abdomen. When the post-transfusion purpura (PTP) panel came back, it revealed an alloantibody against HPA-1b — an uncommon finding, but one that instantly clarified what had happened. What Is Post-Transfusion Purpura? PTP is a rare, delayed transfusion reaction characterized by sudden, severe thrombocytopenia appearing 5–12 days after transfusion. The syndrome occurs most often in individuals who lack the common platelet antigen HPA-1a and have been previously sensitized, typically through pregnancy or prior transfusion. The most common culprit antibody is anti-HPA-1a, but antibodies to other platelet antigens — including HPA-5a, HPA-4a, HPA-3a, and rarely HPA-1b — have been described. Regardless of the specific target, the result is the same: the patient’s immune system destroys both transfused and autologous  platelets, leading to precipitous thrombocytopenia and risk of life-threatening bleeding. A Quick Detour Into HPA Genetics The HPA-1 system is defined by two alleles: HPA-1a, found in roughly 75–95% of most populations. HPA-1b, a minor allele whose frequency ranges from 10–24% in many European and Middle Eastern groups, but is <1% in East Asian populations. This population variation matters. In regions where HPA-1b is rare, like the US, compatible donors for patients with anti-HPA-1b can often be found locally, as most platelet units will be negative for HPA-1b. In the US, sourcing units for patients with anti-HPA-a1 is the reverse — the search for HPA-1b-positive, 1a-negative donors is extraordinarily difficult. Diagnosing PTP PTP should be suspected when: Severe thrombocytopenia develops 5–10 days post-transfusion, There is a paradoxical worsening  of counts after platelet transfusion, and There is no evidence of DIC, HIT, or marrow suppression. Diagnosis is confirmed by detecting platelet-specific alloantibodies in the patient’s serum — most commonly anti-HPA-1a. In this case, however, the antibody was anti-HPA-1b, underscoring that the immunologic mechanism is the same even when the target is rare. Treatment: Why IVIG Works (and Platelets Usually Don’t) The mainstay of treatment is intravenous immunoglobulin (IVIG) — typically 2 g/kg divided over 2–5 days. IVIG acts by saturating Fc receptors, blunting macrophage-mediated platelet destruction, and modulating the immune response. It leads to a platelet recovery in ~85% of reported cases, usually within several days. Plasma exchange can be considered in refractory cases or when IVIG is unavailable, though evidence is limited. What doesn’t  work well is platelet transfusion. Even HPA-matched platelets are often rapidly destroyed in the presence of circulating antibody. Their use is generally reserved for life-threatening bleeding when IVIG has failed or is contraindicated. Reports of transient benefit exist, but consistent success is rare. For long-term management, future RBC transfusions should be washed to remove residual platelets and platelet antigens, and HPA-compatible platelets should be considered to avoid re-exposure and further alloimmunization. Reflection From the Bench This case was a reminder that transfusion medicine sits at the crossroads of immunology and critical care. PTP may be rare, but when it strikes, it can upend a patient’s course and confound even seasoned teams. The irony of PTP is striking: transfused platelets meant to heal instead trigger the destruction of every platelet in circulation. But timely recognition, serologic confirmation, and early IVIG can turn the tide — and save both platelets and lives. When I called hematology with the antibody result today, they immediately pivoted to planning for HPA-matched support before the patient’s next surgery. That’s the value of diagnosis — not just knowing what went wrong, but knowing how to protect the patient the next time around.

When the phone rings mid-transfusion and the words “the patient is hypotensive”  hit your ears, there’s a short list of life-threatening reactions you can’t afford to miss. Four share a similar opening act — fever, hypotension, and sometimes respiratory distress. The fifth looks different but can end the same way if unrecognized. Here’s how to triage the call, fast. 1️⃣ Anaphylaxis Clue:  Sudden hypotension, respiratory distress, flushing, or urticaria — often within minutes  of starting the unit. Ask:  “Did the team give epinephrine?” If they didn’t, that’s step one. Stop the transfusion, keep the line open with saline, and treat per anaphylaxis protocol. Later, you’ll think about IgA deficiency and washed products — but right now, it’s airway, breathing, circulation. 2️⃣ Septic Transfusion Reaction Clue:  Fever and rigors that escalate to shock, often during or shortly after transfusion. Ask:  “Did the team send blood cultures and start antibiotics?” Stop the transfusion immediately and culture both  patient and product. Gram-negative sepsis from a contaminated platelet or red cell unit can mimic anaphylaxis in its speed. 3️⃣ TRALI (Transfusion-Related Acute Lung Injury) Clue:  New or worsening hypoxia and bilateral infiltrates within 6 hours of transfusion, without signs of circulatory overload. Ask:  “Did the oxygen saturation drop or the O₂ requirement go up?” If yes, order a chest X-ray. This is non-cardiogenic pulmonary edema — no diuretics, no fluids, just supportive care and notification to the blood bank. 4️⃣ Acute Hemolytic Transfusion Reaction (AHTR) Clue:  Fever, flank or back pain, hypotension, dark urine, or a sudden rise in bilirubin. Ask:  “Can you send a DAT and haptoglobin?” This one’s about clerical error until proven otherwise. Check patient and unit IDs, call the blood bank, and prepare for aggressive hydration to protect the kidneys. 5️⃣ TACO (Transfusion-Associated Circulatory Overload) Clue:  Hypertension, dyspnea, pulmonary edema, elevated BNP — usually in patients with limited cardiac reserve. Ask:  “Did the team give diuretics, and did the patient respond?” Unlike TRALI, TACO should  improve with diuresis. Prevention is key: slow rates, split units, pre-dose furosemide when indicated. 🩸 Putting It All Together Reaction BP Trend Fever Resp Distress Key Test / Treatment Anaphylaxis ↓ ± + Epinephrine Septic ↓ + ± Cultures + Antibiotics TRALI ↓ ± + CXR → Non-cardiogenic edema AHTR ↓ + ± DAT / Haptoglobin TACO ↑ – + Diuretics → Improves Bottom line: When every minute matters, think pattern-recognition first, paperwork later. Five questions can save a life — and keep you calm when the call comes in.

Every so often a case comes along that refuses to fit into our tidy categories. An adult male presented to the emergency department with profound weakness and striking jaundice. His hemoglobin was 3.7 g/dL, yet he was mentating normally and his lactate was within range — clear evidence of physiologic compensation. The chemistry panel featured a total bilirubin >70 mg/dL, direct fraction ≈ 40 mg/dL, with biliary dilation on CT abdomen/pelvis. On the hematology side, LDH was elevated, haptoglobin undetectable, and the antibody screen revealed a warm autoantibody. Parsing the Pattern At first pass, this looks like hemolysis. Severe anemia, high indirect bilirubin, low haptoglobin, elevated LDH — all the hallmarks are there. But a direct fraction comprising more than half the total complicates the picture: pure hemolysis shouldn’t yield that much conjugated bilirubin. That left two possibilities running in parallel: Primary biliary obstruction (choledocholithiasis, mass, or stricture). Secondary cholestasis from sustained hemolytic load — the liver overwhelmed by the ongoing destruction and turnover of red cells. The patient’s stability pointed toward chronicity. A hemoglobin of 3.7 g/dL with preserved mentation doesn’t happen overnight. This was the physiology of slow, compensated hemolysis finally tipping into hepatic decompensation. Hemolysis Meets Cholestasis In warm autoimmune hemolytic anemia (AIHA), extravascular destruction can be relentless but insidious. Over weeks to months, bilirubin production rises and the liver adapts — upregulating conjugation and secretion. Eventually, canalicular transport capacity becomes the rate-limiting step. The bile becomes supersaturated with bilirubin diglucuronide, predisposing to pigment stone formation and sometimes true biliary obstruction. At that point, the chemistry shifts: direct hyperbilirubinemia emerges, not because the process stopped being hemolytic, but because the liver and biliary tree have been drawn into the downstream pathology. The biliary dilation on CT fits perfectly — not as a primary obstruction, but as a secondary phenomenon of chronic pigment overload. Testing in Context The serologic workup tied it together. Positive DAT with warm autoantibody → ongoing immune hemolysis. Elevated LDH and absent haptoglobin → hemolytic physiology confirmed. Normal lactate and preserved mental status → chronic compensation. The picture that emerged was not an acute biliary event but chronic AIHA complicated by secondary cholestasis, possibly with choledocholithiasis from pigment stones. Biliary Workup MRCP revealed subtle hilar ductal thickening, raising concern for an underlying cholangiocarcinoma. Yet the broader picture didn’t cooperate: tumor markers and an autoimmune cholangiopathy panel were unremarkable. To clarify, an ERCP was performed — several darkly pigmented stones were extracted, and brushings of the bile duct were sent for cytology. No malignant cells were identified. The findings reinforced the idea of secondary  biliary involvement rather than a primary neoplasm. The obstruction appeared mechanical but self-limited, the likely consequence of pigment stone formation in the setting of chronic hemolysis. It was a reminder that when the biliary tree becomes the downstream casualty of hematologic disease, imaging can mimic malignancy and tumor markers can mislead. Takeaway This case reminds me how rarely biology stays within our categorical lines. Direct hyperbilirubinemia does not exclude hemolysis when destruction has been sustained enough to overwhelm excretory capacity. It’s the intersection we rarely see illustrated in textbooks: where hemolysis becomes overwhelming, the liver becomes a bottleneck, and “prehepatic” injury evolves into a mixed cholestatic picture. Sometimes the right answer really is “both.”

The patient was a premature infant, six weeks old and just 2.5 kilograms, already on ECMO for primary cardiopulmonary failure. Sepsis developed secondarily, and the critical-care team requested plasmapheresis for a presumed cytokine storm — a Category III indication  under the current ASFA guidelines. On paper, the rationale made sense. But when I calculated the total blood volume — only 250 mL  (≈ 100 mL/kg for a premature infant) — it was immediately clear this baby was too small for the machine. The Terumo technical support representative confirmed the following minimum specifications  for therapeutic plasma exchange: 30 cm:  Minimum height the system can accept 2 kg:  Minimum weight the system can accept 300 mL:  Minimum total blood volume (manual entry) 10 %:  Minimum hematocrit 0.5 L:  Minimum plasma volume (machine default = 1.0 L) 25 kg:  Minimum weight for automatic TBV calculation Despite meeting the weight requirement, the patient’s total blood volume was below the system’s operational threshold. The procedure was simply not possible. After discussing options with the ICU team, we recommended whole blood exchange  instead — a technically feasible alternative that allowed for cytokine and toxin removal within the constraints of neonatal physiology. This case underscored an important reality: sometimes the limits we face are not physiologic but mechanical. Even when a treatment is conceptually justified, our instruments may not yet be scaled to our smallest and most fragile patients. Until apheresis technology evolves to meet neonatal demands, these moments will remain a quiet reminder that innovation in transfusion medicine isn’t only about what  we can do — it’s also about who  we can safely do it for.

The antibody screen looked straightforward at first glance — an O positive patient with apparent anti-D reactivity in plasma. But the autocontrol was positive, and the eluate was a panagglutinin. Those two results change the entire story. Working the Differential When a D-positive patient’s plasma reacts like anti-D, the immediate differentials are familiar: Partial D variant (missing epitope exposure) Passive anti-D (recent RhIg or IVIG) Autoantibody with apparent Rh specificity Each of these has a characteristic fingerprint. A partial D can produce alloanti-D, but that’s rare in a serologically D-positive person without prior exposure, and the eluate would mirror the plasma pattern, not broaden to panreactivity. Passive anti-D behaves cleanly: plasma reacts like anti-D, eluate is negative or weakly specific, and there’s a clear administration history. What we had was different: a positive autocontrol and a panreactive eluate.That combination eliminates the first two possibilities. The reactivity isn’t alloimmune or passive — it’s autoimmune. The Testing Trail The workup unfolded in layers: Antibody screen — positive with a D-like pattern. Antibody identification panel — strengthened reactivity with D-positive cells, weaker or negative with D-negative cells, suggesting “anti-D.” Autocontrol — positive, establishing that the antibody also reacts with the patient’s own RBCs. Elution study — recovered antibody from patient RBCs showed panreactivity  against all reagent cells. That last result is the pivot point. When an eluate reacts with every cell tested, regardless of Rh type, it means the antibody bound in vivo is not truly D-specific. It’s reacting broadly, most often with epitopes shared across the Rh complex. The apparent anti-D in plasma was the “tip” of the reaction spectrum; concentrating the antibody in the eluate revealed its full range. Understanding the Mechanism This pattern — an apparent anti-D that becomes panreactive on elution — is classic for autoantibodies with relative Rh specificity. Several studies have shown that the Rh complex is a common autoantigenic target in warm AIHA. Barker et al. demonstrated that autoantibodies from AIHA patients could immunoprecipitate Rh-associated polypeptides, confirming that these antibodies truly interact with the Rh complex [1].Later, Iwamoto et al. mapped this reactivity to extracellular peptide loops of Rh antigens (RhD, cE, ce, CE), showing that the apparent specificity stems from how these antigens share structural epitopes [2]. That explains why plasma reactivity can look D-restricted — the antibody’s affinity may be stronger for cells expressing D — but once concentrated, the cross-reactivity becomes universal. Issitt and Pavone and later Henry et al. described this as the “false specificity” of Rh-directed autoantibodies: antibodies that seem to be anti-D, anti-e, or anti-C but are actually targeting shared determinants like Hr, Hro, or Rh34 [3,4]. Clinical Handling In this case, the patient had no evidence of hemolysis and was evaluated in the outpatient setting for routine pretransfusion testing. We were able to rule out any underlying alloantibodies on the work up, and when transfusion was later anticipated, we selected a D-negative unit out of caution. The transfusion was uneventful — confirming that the pattern was serologic, not pathologic. Why It Matters The take-home message isn’t about the D antigen at all — it’s about pattern recognition in serology . When plasma looks specific but the eluate doesn’t, the specificity is probably illusionary. The positive autocontrol and panagglutinin eluate are the signposts pointing away from alloimmunization and toward autoimmunity — specifically, Rh-complex targeting. In documentation, this deserves clarity: “Warm autoantibody with apparent anti-D specificity. Eluate panreactive. No evidence of alloanti-D.” It’s a small notation that prevents a future technologist from re-investigating a mystery that isn’t one — and prevents a clinician from worrying about sensitization that never occurred. References Barker JE et al. J Clin Invest.  1989;84(3):1010–1015. Iwamoto S et al. Blood.  1995;86(1):341–348. Issitt PD, Pavone B. Transfusion.  1978;18(6):702–708. Henry SM et al. Vox Sang.  1987;52(3):193–198.

1 | Finding the rhythm of replacement When people talk about plasma exchange, they usually focus on what  to replace. Less often discussed is how often  we can safely do it. Frequency determines not just antibody clearance but also coagulopathy, albumin balance, and overall tolerance. Replacement fluid and schedule are inseparable — each constrains the other. 2 | Albumin kinetics – recovery and depletion Each 1.0 plasma-volume exchange removes roughly 60–70 % of circulating proteins, albumin included.The liver replaces about 15–20 grams of albumin per day, enough for partial recovery in 24 hours but not full repletion until three to five days later. Even when using 5 % albumin as the replacement fluid, the patient remains in negative protein balance. The solution restores volume and some oncotic pressure , but not total protein mass . Studies have shown that after several consecutive exchanges, even when spaced 48 hours apart, serum albumin and total protein falls. Patients can develop dependent edema or fatigue — subtle, cumulative signs of depletion. 3 | Coagulation factors – the real rate-limiter Albumin replacement also removes the clotting proteins that plasma would otherwise supply. Each albumin-only exchange removes about 60% of plasma fibrinogen, and hepatic synthesis restores only about 60% of that loss over 48 hours. Two daily albumin exchanges in a row can easily drive fibrinogen below 100 mg/dL, the level where bleeding risk becomes clinically relevant. While daily TPE with albumin is generally avoided, logistics can sometimes demand it. Fibrinogen should be checked after two daily albumin TPEs. If it’s low and further daily therapy is unavoidable, switch part or all of the replacement to plasma. For isolated hypofibrinogenemia in an otherwise stable patient, cryoprecipitate can be given instead of altering the entire replacement plan. Plasma-based replacement (as in TTP) sidesteps this issue entirely, because it replenishes what’s removed. 4 | Antibody redistribution – why spacing matters Only about half of circulating IgG lives in the vascular space. The rest resides in tissues and slowly diffuses back into plasma over 12–24 hours. Performing exchanges too close together means removing replacement albumin before those extravascular antibodies re-equilibrate. Spacing sessions every 48 hours allows the newly mobilized antibody pool to enter plasma, improving clearance efficiency and reducing unnecessary protein loss. It also coincides neatly with the time course of fibrinogen recovery — physiology and pharmacokinetics in agreement. 5 | Typical schedules by indication Indication Type Replacement Fluid Frequency Physiologic Rationale TTP / ADAMTS13 deficiency 100 % FFP Daily until platelet recovery Enzyme repletion + inhibitor removal outweigh coagulopathy risk GBS / MG / NMO 100 % albumin Every 48 h × 5 exchanges Allows antibody re-equilibration + fibrinogen recovery ANCA / anti-GBM vasculitis Albumin ± plasma Daily × 2–3 → every 48 h Balances clearance against factor depletion Chronic or maintenance TPE Albumin ± ≤ 30 % crystalloid 2–3 × per week Prevents cumulative protein loss 6 | Clinical guardrails Monitor fibrinogen, albumin, and ionized calcium at baseline and every two to three sessions. Avoid albumin-only exchanges within 24 hours of any invasive procedure. If fibrinogen < 100 mg/dL, add plasma or give cryo before proceeding. Remember that “daily” in published series often means weekdays only  — those weekend pauses are physiologic recovery periods in disguise. 7 | Takeaway Replacement composition and timing aren’t separate decisions. Albumin-only exchanges can safely run for two consecutive days if unavoidable, but beyond that, coagulopathy becomes the constraint. For autoimmune antibody disorders, an every-other-day rhythm improves efficiency and safety. For plasma-dependent disorders such as TTP, daily plasma exchanges remain essential until the disease turns the corner. The rhythm of plasma exchange isn’t set by habit or scheduling convenience — it’s written in the half-lives of the proteins we remove and the ones the body must rebuild.

1 | A brief historical arc In the early years of therapeutic plasma exchange (TPE), replacement was simple: plasma when coagulation factors were needed, 5 % albumin when they were not. Through the 1980s and 1990s, a few groups began experimenting with albumin–saline mixtures to stretch resources and probe the physiology of volume replacement. The results were instructive. Larger saline fractions consistently lowered oncotic pressure, triggered transient hypotension, and produced mild metabolic acidosis. By the late 1990s, most centers had returned to albumin-dominant replacement, reserving plasma for specific indications and using small amounts of crystalloid only for circuit priming, rinseback, or minor volume adjustments. 2 | The physiology — why saline isn’t “neutral” Oncotic pressure: Albumin preserves intravascular volume; saline does not. When saline replaces plasma in large proportions, intravascular volume can fall even as total volume looks adequate. Chloride load and acid–base balance: 0.9 % NaCl carries 154 mmol/L of chloride and a strong-ion difference of 0, which drives hyperchloremic metabolic acidosis. Balanced crystalloids such as Lactated Ringer’s and Plasma-Lyte A include buffers (lactate, acetate, gluconate) and have positive SIDs, making them acid–base neutral or mildly alkalinizing. Renal perfusion: Hyperchloremia activates the macula densa and causes afferent arteriolar constriction, reducing glomerular filtration. That link between chloride load and renal perfusion is one reason large critical-care trials now favor balanced crystalloids over saline. 3 | Guidelines in brief ASFA 2023: Albumin and plasma remain the mainstays. Crystalloids appear only in technical notes, usually as minor adjuncts. Canadian Blood Services: “The most commonly used replacement fluid is 5 % albumin… some centres also use normal saline in combination with albumin or plasma, though this practice is increasingly uncommon.” AJKD Nephrology Core Curriculum 2023: For cost containment, mixtures such as 80:20 albumin:saline are acceptable, with a practical upper limit around 30 % crystalloid. Across documents, the message is consistent: albumin for most indications, plasma when factors are needed, and crystalloids only in modest proportion. 4 | How crystalloids are used today Default:  100 % 5 % albumin for non-factor indications. Plasma:  for TTP and other settings requiring factor repletion. Crystalloids:  used mainly for circuit priming and rinseback, ≤ 20–30 % of the replacement volume when cost or volume considerations apply, and preference for balanced crystalloids over saline to avoid chloride-driven acidosis. Why not more saline? Beyond small fractions, you gain nothing physiologically and risk hyperchloremic acidosis, hypotension, and renal stress — all without oncotic support. 5 | Takeaway Crystalloids do have a place in TPE — but it’s a supporting role. The foundation remains albumin, with plasma added when coagulation factors are required. When crystalloids are used, keep them to no more than about one-third of the exchange volume and choose balanced solutions like Plasma-Lyte A or Lactated Ringer’s whenever possible. It’s a small composition detail in a large-volume therapy — but over several liters, those chloride ions and milliequivalents of buffer can make a measurable difference.

The Overlooked Half of the Exchange When we talk about plasma exchange, most of the conversation centers on what we’re removing — antibodies, paraproteins, cytokines. But replacement fluid is the other half of the equation. It must maintain intravascular volume and oncotic pressure, and sometimes also return essential plasma proteins like clotting factors. Choosing the right replacement fluid is one of the most important clinical judgments in apheresis. It affects safety, hemostasis, and the overall trajectory of a patient’s recovery far more than most order sets acknowledge. The Options Menu Fluid What It Brings When It Shines Notes 5% Albumin Volume and oncotic pressure Stable autoimmune or neurologic diseases May worsen bleeding risk if used early post-op or in coagulopathic patients; lacks clotting factors and immunoglobulins. Fresh Frozen Plasma (FFP) Coagulation factors, fibrinogen, and volume TTP, pre- and early post-transplant desensitization, active bleeding or bleeding diathesis, coagulopathy Risk of allergic reactions, TRALI, volume overload; slower thaw-to-infusion logistics. Cryo-poor Plasma Volume replacement with reduced fibrinogen Refractory TTP Rarely used; availability limited. Saline (adjunct) Volume expander Used with albumin for partial replacement Can dilute plasma proteins if overused; typically limited to ≤20–25 % of total replacement volume. Combination strategies: A 50 : 50 replacement can balance safety and practicality. Always run the fluid you want to “stick around" at the end of the procedure. For saline : albumin , run albumin last. For albumin : FFP , run FFP last. Clinical Scenarios — Matching the Fluid to the Patient TTP: 100 % FFP. You’re replacing the very factors the patient lacks, especially ADAMTS13 and other coag proteins essential for recovery. Transplant-related Apheresis: Desensitization:  Use FFP before transplant and generally for 1–2 weeks post-transplant, depending on stability and laboratory values (fibrinogen, platelets, INR). Antibody-Mediated Rejection (AMR) Post-Transplant:  Replacement choice depends on time since surgery and concurrent risks. In early rejection with bleeding risk, use FFP; later or stable cases can transition to albumin or a mix. Other Antibody-Mediated Diseases (e.g., MG, CREST, etc.): Albumin is typically adequate. However, for syndromes with vasculopathy or active bleeding (such as diffuse alveolar hemorrhage), use FFP until bleeding risk resolves. Liver Failure or DIC: Therapeutic plasma exchange in these settings is uncommon and typically limited to specialized protocols (for example, acute liver failure with hyperammonemia or toxin removal). When performed, FFP is used to replace lost function and mitigate coagulopathy. Myths & Misconceptions “Albumin is always safer.” Not when coagulation support is needed — context determines risk. “FFP is only for TTP.” It’s also indicated when hemostatic balance is fragile, such as peri-transplant or with bleeding vasculopathies. “Replacement fluid choice doesn’t matter.” It quietly dictates post-procedure stability, especially in surgical and critically ill patients. The Quiet Art of Replacement Replacement fluid selection looks mundane on paper, but it’s where clinical judgment lives. It’s the difference between doing an exchange and doing it wisely. Protocols provide the framework; experience fills in the nuance — knowing when to mix, when to taper, and when to pivot from albumin to plasma because the numbers (or the drain output) tell you to. In apheresis, the machines may be automated, but judgment isn’t. The fluid you choose — and the order you run it — still depends on the most analog tool we have: your brain.

This morning on the apheresis service, I saw a familiar face — one of our regular outpatients. He’s four weeks out from a total knee replacement and on baby aspirin twice a day. The nurse asked the inevitable question: “He’s anticoagulated…won’t he bleed if we do TPE?” It’s the instinctive worry. But the truth is more nuanced: anticoagulated  does not automatically mean high bleeding risk . Here’s how I think about it. 🔎How TPE and Anticoagulants Interact 1. Does TPE clear the drug? Heparin (UFH/LMWH):  cleared; anti-Xa activity drops across an exchange. DOACs:  variably removed; repeated procedures can lower levels significantly. Warfarin:  factor removal is the issue. Albumin replacement can raise INR by ~2 points — but that lab bump doesn’t automatically equal bleeding. 2. If so, should the dose be adjusted? Heparin:  often needs retitration  post-procedure. DOACs:  for infrequent outpatient TPE, dose after the run; for frequent or high-risk exchanges, consider anti-Xa checks or temporary heparin bridging. Warfarin:  no standardized pre-emptive adjustment; manage to clinical context, not just the transient INR spike. 3. How does circuit anticoagulation interact with systemic anticoagulation? TPE runs on citrate , which is normally metabolized quickly by the liver — so there’s no lingering systemic anticoagulation after the run. Exception:  in significant liver disease, citrate clearance is impaired. Combine that with systemic anticoagulants and the bleeding risk calculus gets trickier. 4. If bleeding starts, what can I reverse? Heparin → protamine Warfarin → PCC or vitamin K DOACs → idarucizumab (dabigatran) or andexanet (Xa inhibitors), if available Antiplatelets → no direct reversal; platelet transfusion if clinically indicated 5. What about antiplatelet agents? TPE doesn’t target platelets, but some are lost as collateral. Short courses:  usually low risk. Prolonged courses (>10 procedures):  bleeding risk rises when combined with anti-platelet agents. 🩸 Baseline hemostasis effects of TPE Albumin replacement  removes coag factors (esp. fibrinogen). Labs look “coagulopathic” post-exchange, but fibrinogen and factor VIII/vWF rebound within 24–48 h. Short courses:  bleeding is uncommon when calcium is managed and replacement chosen wisely. Long/intensive series + antiplatelets or liver disease:  bleeding risk is real and cumulative. 💡 Practical moves DOAC outpatient:  give the dose after TPE; monitor or bridge if procedures are frequent. Heparin inpatient:  expect anti-Xa to drop; plan a post-procedure check and adjust. Warfarin:  anticipate INR bump; don’t reflexively “correct” unless clinical bleeding or urgent hemostasis is needed. Antiplatelets:  not a contraindication; risk rises with longer TPE series. Outpatients with PIVs:  apply a firm pressure dressing  after removal. Even with “low-risk” anticoagulants, small venipuncture sites can ooze more than expected, and a pressure wrap reduces callbacks for bleeding. 🌟 Closing thought An anticoagulated patient on TPE does not  automatically equal bleeding. The real questions are: which drug, how often, what’s the replacement strategy, and what’s the patient’s baseline risk? For my patient today — aspirin, four weeks post-op — no intervention was needed. The art of apheresis is resisting reflexes, weighing real risks, and tailoring judgment to the person in front of you.

The other day, I asked an AI model about the Diego blood group system. It gave me a slick, confident answer — beautifully formatted, authoritative in tone — and completely wrong. If I were a patient, or even a busy clinician, I might not have caught it. But as a transfusion medicine physician, I knew immediately: this was a hallucination. And here’s the kicker — hallucinations like this aren’t just occasional glitches. They’re mathematically inevitable. The Myth of the Perfect AI Recent studies, including some from OpenAI itself, show that no matter how advanced large language models become, they will sometimes generate false information. That’s not because they’re “bad” or because engineers haven’t worked hard enough. It’s built into how they function. AI predicts the most likely next word, not the absolute truth. For common facts, it does pretty well. But for rare details — like unusual antigens, edge-case transfusion reactions, or cell therapy nuances — the statistical floor drops out. It’s harder to predict the next word for a rare scenario or very nuanced context. In these situations, the model is more likely to “make something up” than to leave a blank or express uncertainty. And in medicine, “making something up” isn’t just embarrassing. It’s dangerous. Why This Is Good News for Workers For those of us working in medicine, this is actually good news. Hallucinations prove that AI isn’t an autonomous replacement — it’s a sophisticated tool that still needs us. AI will be able to: Spot patterns in antibody panels faster than a human Suggest the most efficient inventory allocation Draft a transfusion reaction note in seconds But it will never guarantee accuracy in the cases that matter most. Rare antigens. Borderline transfusion decisions. Patients whose context changes the entire equation. Those are exactly the situations where hallucinations spike — and where human oversight is non-negotiable. As long as hallucinations exist, so does the need for human experts. For laboratorians and transfusion specialists, that’s not just job security — it’s reassurance that expertise remains indispensable. The Hybrid Future So what does the future of transfusion medicine look like in the AI era? I think of it as a “calculator moment.” AI will make our work faster, broader, and more efficient. It will handle the rote paperwork, surface the guidelines, and flag patterns across massive datasets that no human could scan in real time. But it won’t replace the expert at the bench or the physician making the final call. Instead, our role becomes even more vital: verifying, contextualizing, and deciding when the model is wrong. That’s not a bug in the system. That’s the point. Closing Thoughts When I asked the AI about Diego, it hallucinated. A transfusion medicine physician wouldn’t. That difference — the human check, the lived expertise — is what keeps medicine safe. AI hallucinations may be inevitable. But so is the ongoing need for human expertise in medicine. If anything, the rise of AI doesn’t erase our roles. It makes them stronger.

I’ve been out of training just long enough to start thinking about the long term. Over the years, I’ve sat through countless wellness talks and curricula, each with its own prescriptions: resilience workshops, mindfulness modules, burnout prevention checklists. Some were useful, many felt hollow. None fully captured what I’ve come to understand about how we sustain ourselves in medicine. So, I’ve started developing my own way of thinking — a kind of unified theory of wellness. The other night, I sat on the porch for the first time since moving here. The air was perfect — not too hot, not really chilly either. My husband and I watched people walk by, listened to the birds, and talked. Nothing urgent, nothing scheduled. Just being together. It felt like liquid time, the kind of moment where the clock drops away. Later I remembered there’s a Greek word for this: kairos . Unlike chronos  — the linear time of calendars and deadlines — kairos is time outside of time, the opportune moment, the kind of pause that feels like a gift. Inviting Kairos You can’t summon kairos the way you punch a clock. It doesn’t obey effort or demand. But you can  invite it. You can create spaces where it’s welcome — by slowing down, softening your pace, lingering a little longer. Kairos time can’t be commanded. It comes as grace — a quiet reminder that I am more than the clock that rules me. That evening on the porch was kairos. So is watching my cats in a sunspot, melted together in a beam of light. These moments can’t be forced, but when they arrive, they restore me. Curiosity as a Vital Sign If kairos is a gift, curiosity is the sign that I’m well enough to receive it. I’ve noticed that curiosity is the first thing to go when burnout creeps in  — the canary in the coal mine. When I’m exhausted or overextended, my questions dry up. I stop wanting to learn, explore, play. That’s why I think curiosity is one of the best metrics of mental health. It’s not only a measure of wellness, it’s also a practice that sustains wellness. To stay curious is to stay open to life. Mindfulness as Curious Endurance So where does mindfulness fit in? I think we often misunderstand it as sterile calmness, a blank mind. To me, mindfulness is much simpler: it’s the practice of remaining curious while uncomfortable . Restless in meditation? Be curious. Hungry, anxious, tired? Stay with it — not to fix it, but to see it. Mindfulness is a way of holding discomfort gently, asking questions instead of recoiling. It’s what makes room for kairos to slip in. Food as Spiritual Practice I also believe food is part of wellness in a way that’s both practical and spiritual. Eating isn’t just fuel; it’s memory, texture, community, story. When I accept food as spiritual, I eat with curiosity. I notice flavors, origins, the act of sharing. Meals, too, can open into kairos when approached with attention. A Theory of Wellness When I put all this together, I see a theory of wellness forming: Curiosity is the canary.  Its presence or absence tells me how I’m doing. Mindfulness is curious endurance.  It keeps me open even when life is uncomfortable. Kairos is the gift.  I can invite it but never command it. When it comes, it restores me. Food is spiritual.  Eating with curiosity connects me back to the world and to myself. Wellness, then, is not about perfection, or squeezing one more habit into the day. It’s about staying open enough to be curious, slowing down enough to invite kairos, and receiving those timeless gifts when they arrive. Closing On the porch that night, with birdsong and street sounds in the air, kairos found me. It always comes unannounced, and always feels like grace. My job is simply to make space, stay curious, and be ready to recognize the gift when it arrives. Curiosity is the path into kairos. And kairos is where curiosity learns to breathe.

In Part Two, we followed the fork in the road: cellular and tissue-based products that meet all four criteria in 21 CFR 1271.10(a) can stay in the lighter 361  pathway, while those that don’t become 351 biologics.  Now let’s zoom in fully on the 361 side — the “tissue world.” What Counts as a 361 Tissue? Classic 361 HCT/Ps  include: Tendons  → structural grafts used in orthopedic repair. Corneas  → restore vision by replacing a damaged cornea. Skin grafts  → cover burns or wounds. Bone grafts  → structural repair of skeletal defects. Amniotic membranes  → used as wound coverings. These are all minimally manipulated  and used for their original, homologous function  in the body. They’re not combined with active drugs or devices, and most are structural rather than systemic. That’s why they can remain in the 361 category. Reproductive Tissues: A Special Subset Reproductive tissues also fall under the 361 framework, but they’re worth highlighting separately because they are an explicit exception to the “systemic effect” rule. Examples : semen, oocytes, embryos, ovarian and testicular tissue. Why 361?  They are minimally manipulated (collected, frozen, thawed) and used for their homologous function — to enable reproduction. The carve-out:  Most HCT/Ps must not depend on systemic or metabolic activity to qualify as 361, but reproductive cells and tissues are the exception. Without this carve-out, assisted reproduction would require INDs and BLAs — an impossible barrier for routine fertility practice. Like other 361 tissues, reproductive HCT/Ps are regulated under 21 CFR 1271 Subparts A–D : donor screening/testing, registration, and good tissue practice. FDA also issues special guidance for communicable disease testing in this context. Why Minimal Manipulation + Homologous Use Matters These two criteria are the backbone of the 361 definition. Minimal manipulation  means the processing doesn’t alter the tissue’s relevant structural or biological characteristics. Freezing, shaping, or disinfecting = fine. Digesting into cells or culturing extensively = not minimal. Homologous use  means the product is used for the same basic function in the recipient that it served in the donor. Cornea → restores sight (same function). Bone → provides structural support (same function). Amnion → covers wounds (same barrier function). Sperm → fertilizes eggs (same function). Stay within those guardrails, and you remain a 361 product. Step outside, and you move into 351. When Tissues “Flip” Into 351 Territory Many products marketed as “stem cell” or “regenerative” therapies are actually tissues that don’t meet the 361 criteria . Amniotic membrane : If marketed simply as a wound covering = 361. If marketed as a source of stem cells with regenerative potential = 351. Bone grafts : Structural bone chips or paste = 361. Demineralized bone matrix marketed for its “inductive” properties to stimulate new bone growth = 351. Adipose tissue : Fat grafting for cushioning = 361. Isolating stromal vascular fraction for systemic regenerative claims = 351. The rule of thumb: once you claim systemic or metabolic effects—or manipulate the tissue beyond its natural form—you’ve crossed into biologics. Regulations That Apply 361 HCT/Ps are regulated under: PHS Act §361  → authority to prevent communicable disease transmission. 21 CFR 1271, Subparts A–D  → the tissue rules: Registration and listing of establishments Donor eligibility determination Screening/testing for communicable disease Current good tissue practice (cGTP): clean facilities, recordkeeping, labeling Notably, 361 products are not required to demonstrate clinical efficacy  before use. The regulatory framework is about safety from infection , not effectiveness . Contrast With Blood and 351 Cell Therapies This narrower focus sets 361 tissues apart from other regulated biologics: Blood : Regulated as both a drug and a biologic (FD&C Act + PHS Act), with requirements for manufacturing controls, labeling, and adverse event reporting in addition to donor testing. 351 Cell Therapies : Must prove safety, purity, and potency  through INDs, clinical trials, and BLAs. Every lot is produced under GMP and often requires product-specific release testing. 361 Tissues (including reproductive tissues) : Avoid the heavy biologics framework entirely, so long as they stay minimally manipulated and used homologously. Why It Matters The 361 pathway explains why corneas, tendons, semen, and skin grafts can be transplanted or used clinically every day without going through years of clinical trials. At the same time, it highlights why the FDA is cracking down on “stem cell clinics” that try to stretch 361 definitions beyond recognition. Understanding this distinction helps clarify not only what the law says , but also why some cellular therapies cost thousands and others cost hundreds of thousands.  The difference often comes down to which side of the 351/361 fork a product falls on. 📌 Wrapping Up the Series: Part One : Laws vs. regulations, FDA structure, and why blood is both a drug and a biologic. Part Two : The fork in the road — 351 vs. 361, and how FDA decides. Part Three : The 361 tissue world, including reproductive tissues, its boundaries, and its contrasts with blood and biologics. By untangling the alphabet soup, we can see the underlying logic: each pathway—blood, 351 cell therapies, 361 tissues—grew from the same legal roots but branched into different regulatory frameworks. And knowing those roots helps us understand where cellular therapy is headed next.